Relationship between vitamin D and chronic spontaneous urticaria: a systematic review

Tuchinda, Papapit; Kulthanan, Kanokvalai; Chularojanamontri, Leena; Arunkajohnsak, Sittiroj; Sriussadaporn, Sutin

doi:10.1186/s13601-018-0234-7

Clinical and Translational Allergy

Table 5 Summarized of treatment regimens and outcome of vitamin D supplementation

From: Relationship between vitamin D and chronic spontaneous urticaria: a systematic review

N	Sindher et al. [27]**		Rorie et al. [26]^††		Rasool et al. [25]^§§				Oguz Topal et al. [24]		Boonpiyathad et al. [31]		Ariaee et al. [19]		Dabas et al. [32]
N	1		21	21	48		57		57		50		20		200
Intervention	Vitamin D3 400 IU/day	Vitamin D3 2000 IU/day	Vitamin D3 4000 IU/day	Vitamin D3 600 IU/day	Vitamin D3 60,000 IU/week		Vitamin D3 60,000 IU/week, 4 weeks Hydroxyzine 25 mg/day, 6 weeks Corticosteroid 6 mg/day, 6 weeks		Vitamin D3 300,000 IU/month		Vitamin D2 20,000 IU/day		Vitamin D (unknown form) 50,000 unit/week		Vitamin D (unknown form) Group A Vitamin D 2000 IU/day Group B Vitamin D 60,000 IU/week Group C None
Duration	8 weeks	ND	12 weeks	12 weeks	4 weeks		4 weeks		12 weeks		6 weeks		8 weeks		12 weeks
Vitamin D status (ng/mL)
Before treatment	4.7	ND	28.8 ± 2.2	37.1 ± 3.4	16.98 ± 1.43		18.95 ± 1.42		ND		13 (8–29) median (min–max)		ND		ND
End of treatment	ND	65	56.0 ± 3.9	35.8 ± 2.3	56.74 ± 3.76 (p < 0 .0001)		41.73 ± 2.85 (p < 0.0001)		ND		40 (28–62) median (min–max)		ND		ND
Outcome	Continued to have intermittent urticaria	Complete resolution without antihistamine	Decrease total USS scores (mean ± SE)		VAS score (mean ± SEM)				UAS4 (median(min–max))		UAS7		USS (mean ± SD)		UAS4 (mean)
			15.0 ± 2.9 (p = 0.02)	24.1 ± 4.0	Before	After	Before	After	Before	After	Before	After	Before	After	Before	After 6 weeks	After 12 weeks
					6.7 ± 0.04	5.2 ± 0.70 p = 0.009	6.68 ± 0.40	1.86 ± 0.39 p < 0.0001	21 (0–42.0)	6 (0–21.0) p < 0.001	27 (6–38)	15 (2–33)	235 ± 13.9	11.2 ± 9.6	GroupA
					6.7 ± 0.04	5.2 ± 0.70 p = 0.009	6.68 ± 0.40	1.86 ± 0.39 p < 0.0001	21 (0–42.0)	6 (0–21.0) p < 0.001	27 (6–38)	15 (2–33)	235 ± 13.9	11.2 ± 9.6	11.8 ± 7.6	6.6 ± 6.0	5.3 ± 5.2
					5-D itch score (mean)				CU-Q2oL (median(min–max))		DLQI scores		DLQI scores (mean ± SD)		Group B
					Before	After	Before	After	Before	After	Before	After	Before	After	13.0 ± 8.0	6.4 ± 5.0	4.2 ± 3.5
					14.5 ± 0.72	12.06 ± 1.10 p = 0.007	13.9 ± 0.68	5.01 ± 0.94 p < 0.0001	38 (6.5–115.2)	10.8 (0–43.4) p < 0.001	13 (4–31)	6 (1–20)	10.8 ± 1.6	0.9 ± 4.8	Group C
					14.5 ± 0.72	12.06 ± 1.10 p = 0.007	13.9 ± 0.68	5.01 ± 0.94 p < 0.0001	38 (6.5–115.2)	10.8 (0–43.4) p < 0.001	13 (4–31)	6 (1–20)	10.8 ± 1.6	0.9 ± 4.8	12.9 ± 7.03	8.0 ± 5.7	6.1 ± 4.8

5-D itch score, 5-dimension itch score; CU-Q2oL, Chronic Urticaria Quality of Life Questionnaire; DLQI, Dermatology Life Quality Index; ND, not defined; UAS, urticaria activity score; USS score, the Urticaria Symptom Severity Score; VAS, visual analogue scale
**CSU patients in Sindher et al. was treated with low dose vitamin D3 without response, then the patient was treated with higher dosage of vitamin D3 [26]
^††CSU patients in Rorie et al. were randomized to vitamin D3 4000 IU/day or 600 IU/day [25]
^§§CSU patients in Rasool et al. were randomized to vitamin D3 60,0000 IU/week alone or vitamin D3 60,000 IU/week and hydroxyzine 25 mg/day and corticosteroid 6 mg/day [24]

Back to article page

ISSN: 2045-7022

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com